Saturday, July 15, 2023 9:39:25 PM
My speculation of why Shorts would theoretically switch and hope for a buyout.
- a perfect storm of NWBO positive events is gathering on the horizon
- DCVax will get approval and the first will likely happen this year
- that event will trigger a structural built-in supply of global buyers to start buying NWBO. It will be by Shorts covering, by all categories of New Investors broadly, and of course by big money Institutional Investors (after upgrade to an exchange). Structural because Institutions will typically come to own 70% over time, currently it is 0%.
- the current makeup of NWBO investors are primarily insiders, friendlies, and very knowledgeable longs who basically will not sell.
- Major buyers but no sellers create an environment for uncontrolled price appreciation. That is the problem for Shorts in the nearer term.
- So ironically, a buyout of NWBO would help shorts because it places a buyout price cap on the stock price.
- a perfect storm of NWBO positive events is gathering on the horizon
- DCVax will get approval and the first will likely happen this year
- that event will trigger a structural built-in supply of global buyers to start buying NWBO. It will be by Shorts covering, by all categories of New Investors broadly, and of course by big money Institutional Investors (after upgrade to an exchange). Structural because Institutions will typically come to own 70% over time, currently it is 0%.
- the current makeup of NWBO investors are primarily insiders, friendlies, and very knowledgeable longs who basically will not sell.
- Major buyers but no sellers create an environment for uncontrolled price appreciation. That is the problem for Shorts in the nearer term.
- So ironically, a buyout of NWBO would help shorts because it places a buyout price cap on the stock price.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
